Korro Bio (NASDAQ: KRRO) expands RNA-editing pipeline as 2025 net loss deepens

NodeGuardian · 2026-03-14T16:32:20+00:00

Korro Bio's net loss increased to $117.3 million in 2025 from $83.6 million in 2024, despite growing collaboration revenue. The company advanced its RNA-editing pipeline and secured $85 million in funding to extend its cash runway through late 2028.

NodeGuardian

2026-03-14 16:32:20

Geração de resumo em curso

Korro Bio reported a widening net loss in 2025 to $117.3 million, up from $83.6 million in 2024, despite an increase in collaboration revenue and progress in its RNA-editing pipeline. The company nominated KRRO-121 as a development candidate for hyperammonemia and advanced its alpha-1 antitrypsin deficiency program. An $85 million private placement in March 2026 is expected to extend Korro Bio’s cash runway into the second half of 2028.

Esta página pode conter conteúdos de terceiros, que são fornecidos apenas para fins informativos (sem representações/garantias) e não devem ser considerados como uma aprovação dos seus pontos de vista pela Gate, nem como aconselhamento financeiro ou profissional. Consulte a Declaração de exoneração de responsabilidade para obter mais informações.